Clinical Trials Browser

Approved for marketing × Leukemia, Lymphocytic, Chronic, B-Cell × ibrutinib × Clear all

NCT02437019 2017-03-20

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Approved for marketing

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell